During the height of the COVID-19 pandemic, numerous clinical trials were paused or transitioned, if possible, to virtual or hybrid clinical trials. These types of trials leveraged a variety of modalities, including telemedicine, remote visits, and various sensors or wearable technology.
Not all disease indications or types of trials are suitable for virtual or hybrid clinical trials, although often components of hybrid trials might be suitable for most studies.
